Shingo Toyoda

Sayama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors.

Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors.

Journal: Anticancer research

Published: May 26, 2026

Efficacy, safety, and treatment feasibility of pembrolizumab plus lenvatinib in patients aged 75 years or older with advanced renal cell carcinoma: a Japanese multicenter retrospective study.

Efficacy, safety, and treatment feasibility of pembrolizumab plus lenvatinib in patients aged 75 years or older with advanced renal cell carcinoma: a Japanese multicenter retrospective study.

Journal: International journal of clinical oncology

Published: May 01, 2026

Differential impact of host-related factors on survival outcomes between IO+IO and IO+TKI in metastatic renal cell carcinoma: a multicenter retrospective study.

Differential impact of host-related factors on survival outcomes between IO+IO and IO+TKI in metastatic renal cell carcinoma: a multicenter retrospective study.

Journal: International journal of clinical oncology

Published: April 11, 2026

Development of a Prognostic Model for Patients Aged ≤65 Years With Metastatic Renal Cell Carcinoma.

Development of a Prognostic Model for Patients Aged ≤65 Years With Metastatic Renal Cell Carcinoma.

Journal: Anticancer research

Published: April 02, 2026

Efficacy and safety of first-line immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients on hemodialysis.

Efficacy and safety of first-line immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients on hemodialysis.

Journal: Urologic oncology

Published: April 02, 2026

Development of a prognostic model for elderly patients with metastatic clear cell renal cell carcinoma treated with first-line immuno-oncology combination therapy.

Development of a prognostic model for elderly patients with metastatic clear cell renal cell carcinoma treated with first-line immuno-oncology combination therapy.

Journal: Japanese journal of clinical oncology

Published: March 16, 2026

Comparative Efficacy of First-Line Immune Checkpoint Inhibitor-Based Combination Therapies in Patients With Sarcomatoid Renal Cell Carcinoma: A Japanese Multicenter Cohort Study.

Comparative Efficacy of First-Line Immune Checkpoint Inhibitor-Based Combination Therapies in Patients With Sarcomatoid Renal Cell Carcinoma: A Japanese Multicenter Cohort Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: February 24, 2026

Prevalence and Associated Factors of Erectile Dysfunction in Japanese Adolescent and Young Adult (AYA) Male Cancer Survivors.

Prevalence and Associated Factors of Erectile Dysfunction in Japanese Adolescent and Young Adult (AYA) Male Cancer Survivors.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: January 19, 2026

Impact of prior primary tumor resection on long-term prognosis in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab: a multicenter analysis.

Impact of prior primary tumor resection on long-term prognosis in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab: a multicenter analysis.

Journal: International journal of clinical oncology

Published: December 28, 2025

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line ARPI Therapy.

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line ARPI Therapy.

Journal: The Prostate

Published: December 01, 2025

Cachexia index as a prognostic indicator in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab: multicenter analysis.

Cachexia index as a prognostic indicator in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab: multicenter analysis.

Journal: International journal of clinical oncology

Published: September 23, 2025

Comparative efficacy of immune checkpoint inhibitor combination therapies by metastatic site in metastatic renal cell carcinoma.

Comparative efficacy of immune checkpoint inhibitor combination therapies by metastatic site in metastatic renal cell carcinoma.

Journal: Scientific reports

Published: August 22, 2025

Showing 1-12 of 33

Last Updated: 09/26/2026